Quick Answer
BridgeBio Pharma, Inc. reported Diluted EPS of $3.78 per share (loss) for fiscal year 2025.
BridgeBio Pharma, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.78 | -31.2% |
| 2024 | -$2.88 | +27.1% |
| 2023 | -$3.95 | -21.2% |
| 2022 | -$3.26 | +16.4% |
| 2021 | -$3.90 | -2.6% |
| 2020 | -$3.80 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.95 | -10.5% | +0.0% |
| June 30, 2025 | -$0.95 | -143.6% | -8.0% |
| March 31, 2025 | -$0.88 | -340.0% | -2.3% |
| September 30, 2024 | -$0.86 | +20.4% | -120.5% |
| June 30, 2024 | -$0.39 | +60.2% | -95.0% |
| March 31, 2024 | -$0.20 | +78.3% | +81.5% |
| September 30, 2023 | -$1.08 | -16.1% | -10.2% |
| June 30, 2023 | -$0.98 | -1300.0% | -6.5% |
- BridgeBio Pharma, Inc. showed a decrease of -31.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, BridgeBio Pharma, Inc.’s diluted eps has grown by 0.5% (from $3.80 per share (loss) to $3.78 per share (loss)).
- The most recent figure is from BridgeBio Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: